MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
01 Agosto 2024 - 7:01AM
Business Wire
- Advances company’s ambition to provide fully integrated and
comprehensive solution for viral vector manufacturing
- Mirus Bio’s leading GMP transfection reagents complement
company’s upstream bioprocessing portfolio
- Combined portfolio meets customer needs as demand for novel
modalities grows
MilliporeSigma, the U.S. and Canada Life Science business of
Merck KGaA, Darmstadt, Germany, today announced that the company’s
Life Science business has closed the transaction to acquire Mirus
Bio for approximately US$ 600 million (around € 550 million),
following regulatory clearances and the fulfillment of other
customary closing conditions. The acquisition is a strategic step
towards the company’s ambition to offer solutions for every step of
viral vector manufacturing. It also reinforces the company’s
commitment to supporting customers in advancing cell and gene
therapies from preclinical through commercial production. The Life
Science business of Merck KGaA, Darmstadt, Germany acquired Mirus
Bio from Gamma Biosciences, a life sciences platform established by
global investment firm KKR.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240801851971/en/
MilliporeSigma operators monitoring viral
vector production process at MilliporeSigma's Carlsbad, California
manufacturing facility. (Photo: Business Wire)
"Novel modalities like cell and gene therapies offer tremendous
potential for bringing new curative treatments to patients,” said
Sebastian Arana, Head of Process Solutions, Life Science business
of Merck KGaA, Darmstadt, Germany. “Mirus Bio’s advanced
technology, combined with our bioprocessing expertise and broad
portfolio, will enable us to deliver integrated solutions across
the viral vector value chain and help meet the growing demand for
these life-saving therapies.”
Mirus Bio specializes in the development and commercialization
of transfection reagents, such as TransIT-VirusGEN®. These reagents
play a critical role in the production of viral vector-based gene
therapies. The addition of Mirus Bio’s leading transfection
reagents strengthens MilliporeSigma's upstream portfolio and allows
for an integrated viral vector manufacturing offering.
Mirus Bio’s leading transfection reagents further strengthen
MilliporeSigma’s existing portfolio. The Life Science business of
Merck KGaA, Darmstadt, Germany provides solutions for every step of
the viral vector manufacturing process to advance cell and gene
therapies from preclinical through commercial production. Its
portfolio is one of the broadest in the industry and includes cell
lines, cell culture media, process materials like chemicals,
buffers and enzymes, as well as systems, filters, hardware and
consumables. MilliporeSigma’s expertise covers a variety of viral
vector types, including adeno-associated virus, lentivirus, and
adenovirus. Additionally, the company offers contract testing and
comprehensive CDMO services for viral vector manufacturing,
leveraging three decades of experience supporting cell and gene
therapies.
About the Life Science business of Merck KGaA, Darmstadt,
Germany
The Life Science business of Merck KGaA, Darmstadt, Germany,
which operates as MilliporeSigma in the U.S. and Canada, has more
than 28,000 employees and more than 55 total manufacturing and
testing sites worldwide, with a portfolio of more than 300,000
products focused on scientific discovery, biomanufacturing and
testing services. Merck KGaA, Darmstadt, Germany, a leading science
and technology company, operates across healthcare, life science
and electronics.
Around 63,000 employees work to make a positive difference to
millions of people’s lives every day by creating more joyful and
sustainable ways to live. From providing products and services that
accelerate drug development and manufacturing as well as
discovering unique ways to treat the most challenging diseases to
enabling the intelligence of devices – the company is everywhere.
In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21
billion in 65 countries.
The company holds the global rights to the name and trademark
“Merck” internationally. The only exceptions are the United States
and Canada, where the business sectors of Merck KGaA, Darmstadt,
Germany, operate as MilliporeSigma in life science, EMD Serono in
healthcare and EMD Electronics in electronics. Since its founding
in 1668, scientific exploration and responsible entrepreneurship
have been key to the company’s technological and scientific
advances. To this day, the founding family remains the majority
owner of the publicly listed company. For more information about
Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook
@MilliporeSigma and on LinkedIn.
All Merck KGaA, Darmstadt, Germany news releases are distributed
by email at the same time they become available on the EMD Group
website. In case you are a resident of the U.S. or Canada please go
to www.emdgroup.com/subscribe to register again for your online
subscription of this service as our newly introduced geo-targeting
requires new links in the email. You may later change your
selection or discontinue this service.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801851971/en/
Media Relations Rachel Bloom-Baglin
rachel.bloom-baglin@milliporesigma.com Phone: +1 978 436 1725